SUO 2018: The Platinum Study: Late Effects of Testicular Cancer and Its Treatment
Phoenix, Arizona (UroToday.com) In this talk, Dr. Travis, a pioneer in the field of testicular cancer survivorship, highlights the research to date in the field and the results of the Platinum Study, which focused on the late effects of testicular cancer and its treatments.
SUO 2018: Development of Serum MicroRNA as a Novel and Better Tumor Marker for Testicular Germ Cell Tumor than HCG and AFP
Phoenix, Arizona (UroToday.com) In this first talk by Dr. Kollmannsberger, the focus is on serum micro-RNA’s (miRNA) as a novel and potentially superior tumor marker for testicular germ cell tumors (GCTs) than HCG and AFP.
SUO 2018: Update on the SEMS Trial - Surgery in Early Metastatic Seminoma
Phoenix, Arizona (UroToday.com) Dr. Daneshmand wrapped up the testicular cancer session with an update on the SEMS trial. The current standard of care for node-positive seminoma patients is either radiation or chemotherapy. There has been no change in recommendation for decades. However, as seen by Dr. Travis’ work, these treatments are associated with long-term morbidity, such as 2nd malignancy, cardiovascular toxicity, metabolic syndrome, and pulmonary toxicity. Especially as the cure rates are so high, patients have a long time to develop these toxicities.